YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

iPad Application to Treat Prosodic Deficits in Students With Communication Disorders

Not Applicable

Completed

Conditions: Communication Disorders
Autism

Interventions: Behavioral: iPad Application

First Posted Date: 2013-08-07

Last Posted Date: 2016-06-14

Lead Sponsor: Yale University

Target Recruit Count: 200

Registration Number: NCT01917864

Locations: 🇺🇸
Yale Child Study Center, New Haven, Connecticut, United States

Translational Neuroscience Optimization of GlyT1 Inhibitor

Phase 2

Completed

Conditions: Cognitive Impairments Associated With Schizophrenia

Interventions: Drug: Placebo
Drug: PF-03463275

First Posted Date: 2013-07-30

Last Posted Date: 2024-08-19

Lead Sponsor: Yale University

Target Recruit Count: 71

Registration Number: NCT01911676

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

Pivotal Response Treatment for Children With Autism Spectrum Disorders

Not Applicable

Completed

Conditions: Autism Spectrum Disorders

Interventions: Behavioral: Pivotal Response Training

First Posted Date: 2013-07-26

Last Posted Date: 2020-08-14

Lead Sponsor: Yale University

Target Recruit Count: 40

Registration Number: NCT01908686

Locations: 🇺🇸
Yale Child Study Center - Autism Program, New Haven, Connecticut, United States

Ultrasound Biofeedback for Speech Sound Disorders

Phase 1

Completed

Conditions: Speech Sound Disorders

Interventions: Behavioral: Ultrasound visual feedback

First Posted Date: 2013-07-23

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 35

Registration Number: NCT01905449

Locations: 🇺🇸
Haskins Laboratories, New Haven, Connecticut, United States

PK/PD Comparison of Guanfacine ER and IR

Phase 2

Completed

Conditions: Smoking

Interventions: Drug: Guanfacine

First Posted Date: 2013-07-22

Last Posted Date: 2020-03-06

Lead Sponsor: Yale University

Target Recruit Count: 5

Registration Number: NCT01904526

Locations: 🇺🇸
Yale Center for Clinical Investigations, Yale University, New Haven, Connecticut, United States

The Gut-brain Axis in Food Reward and Alcohol Consumption

Not Applicable

Completed

Conditions: Impulsivity
Alcohol Consumption

Interventions: Dietary Supplement: Phospholean
Dietary Supplement: Placebo

First Posted Date: 2013-07-17

Last Posted Date: 2020-04-03

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT01902069

Locations: 🇺🇸
John B Pierce Laboratory, New Haven, Connecticut, United States

Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents

Not Applicable

Completed

Conditions: Obesity
Insulin Resistance

Interventions: Behavioral: Caloric restrictive diet

First Posted Date: 2013-07-17

Last Posted Date: 2020-03-02

Lead Sponsor: Yale University

Target Recruit Count: 14

Registration Number: NCT01901978

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

A Study to Help People Quit Smoking.

Not Applicable

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Galantamine 16mg
Drug: placebo
Drug: Galantamine 8mg

First Posted Date: 2013-06-18

Last Posted Date: 2020-03-23

Lead Sponsor: Yale University

Target Recruit Count: 60

Registration Number: NCT01880099

Locations: 🇺🇸
Veteran Affairs, West Haven, Connecticut, United States

Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: Lipiodol

First Posted Date: 2013-06-13

Last Posted Date: 2020-04-15

Lead Sponsor: Yale University

Target Recruit Count: 39

Registration Number: NCT01877187

Locations: 🇺🇸
The Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States

Testosterone Replacement for Male Opioid Agonist Maintained Patients

Phase 1

Completed

Conditions: Symptomatic Hypogonadism
Chronic Pain
Opioid Addiction

Interventions: Drug: Testosterone replacement
Other: Waitlist control

First Posted Date: 2013-06-10

Last Posted Date: 2017-06-12

Lead Sponsor: Yale University

Target Recruit Count: 15

Registration Number: NCT01873989

Locations: 🇺🇸
MRU, APT Foundation, Inc, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy